Tawarungruang Chaiwat, Khuntikeo Narong, Chamadol Nittaya, Laopaiboon Vallop, Thuanman Jaruwan, Thinkhamrop Kavin, Kelly Matthew, Thinkhamrop Bandit
Epidemiology and Biostatistics Program, Faculty of Public Health, Khon Kaen University, Khon Kaen, Thailand.
Cholangiocarcinoma Screening and Care Program (CASCAP), Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
BMC Cancer. 2021 May 3;21(1):497. doi: 10.1186/s12885-021-08247-z.
Cholangiocarcinoma (CCA) has been categorized based on tumor location as intrahepatic (ICCA), perihilar (PCCA) or distal (DCCA), and based on the morphology of the tumor of the bile duct as mass forming (MF), periductal infiltrating (PI) or intraductal (ID). To date, there is limited evidence available regarding the survival of CCA among these different anatomical and morphological classifications. This study aimed to evaluate the survival rate and median survival time after curative surgery among CCA patients according to their anatomical and morphological classifications, and to determine the association between these classifications and survival.
This study included CCA patients who underwent curative surgery from the Cholangiocarcinoma Screening and Care Program (CASCAP), Northeast Thailand. The anatomical and morphological classifications were based on pathological findings after surgery. Survival rates of CCA and median survival time since the date of CCA surgery and 95% confidence intervals (CI) were calculated. Multiple cox regression was performed to evaluate factors associated with survival which were quantified by hazard ratios (HR) and their 95% CIs.
Of the 746 CCA patients, 514 had died at the completion of the study which constituted 15,643.6 person-months of data recordings. The incidence rate was 3.3 per 100 patients per month (95% CI: 3.0-3.6), with median survival time of 17.8 months (95% CI: 15.4-20.2), and 5-year survival rate of 24.6% (95% CI: 20.7-28.6). The longest median survival time was 21.8 months (95% CI: 16.3-27.3) while the highest 5-year survival rate of 34.8% (95% CI: 23.8-46.0) occurred in the DCCA group. A combination of anatomical and morphological classifications, PCCA+ID, was associated with the longest median survival time of 40.5 months (95% CI: 17.9-63.0) and the highest 5-year survival rate of 42.6% (95% CI: 25.4-58.9). The ICCA+MF combination was associated with survival (adjusted HR: 1.45; 95% CI: 1.01-2.09; P = 0.013) compared to ICCA+ID patients.
Among patients receiving surgical treatment, those with PCCA+ID had the highest 5-year survival rate, which was higher than in groups classified by only anatomical characteristics. Additionally, the patients with ICCA+MF tended to have unfavorable surgical outcomes. Showed the highest survival association. Therefore, further investigations into CCA imaging should focus on patients with a combination of anatomical and morphological classifications.
胆管癌(CCA)已根据肿瘤位置分为肝内型(ICCA)、肝门周围型(PCCA)或远端型(DCCA),并根据胆管肿瘤的形态分为肿块型(MF)、导管周围浸润型(PI)或导管内型(ID)。迄今为止,关于这些不同解剖学和形态学分类的CCA患者生存率的证据有限。本研究旨在根据CCA患者的解剖学和形态学分类评估根治性手术后的生存率和中位生存时间,并确定这些分类与生存之间的关联。
本研究纳入了来自泰国东北部胆管癌筛查与护理项目(CASCAP)接受根治性手术的CCA患者。解剖学和形态学分类基于手术后的病理结果。计算了CCA的生存率、自CCA手术日期起的中位生存时间及95%置信区间(CI)。进行多因素Cox回归以评估与生存相关的因素,这些因素通过风险比(HR)及其95%CI进行量化。
在746例CCA患者中,514例在研究结束时死亡,构成了15643.6人月的数据记录。发病率为每月每100例患者3.3例(95%CI:3.0 - 3.6),中位生存时间为17.8个月(95%CI:15.4 - 20.2),5年生存率为24.6%(95%CI:20.7 - 28.6)。最长的中位生存时间为21.8个月(95%CI:16.3 - 27.3),而DCCA组的5年生存率最高,为34.8%(95%CI:23.8 - 46.0)。解剖学和形态学分类的组合PCCA + ID与最长的中位生存时间40.5个月(95%CI:17.9 - 63.0)和最高的5年生存率42.6%(95%CI:25.4 - 58.9)相关。与ICCA + ID患者相比,ICCA + MF组合与生存相关(调整后HR:1.45;95%CI:1.01 - 2.09;P = 0.013)。
在接受手术治疗的患者中,PCCA + ID患者的5年生存率最高,高于仅按解剖学特征分类的组。此外,ICCA + MF患者的手术结局往往不佳。显示出最高的生存相关性。因此,对CCA影像学的进一步研究应聚焦于解剖学和形态学分类组合的患者。